glp-1/glucagon dual receptor agonist Efficacy of glucagon-like peptide-1 and estrogen in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes New Developments in Pharmacological Treatment

The combination of high disease burden and commercial insurance or out-of-pocket payment capability makes Gulf markets commercially attractive despite their small absolute size

Ethics declarations Competing interests Torsten Haack, Youssef Hijazi, Lenore Teichert, Veronique Tavernier, Iina Laitinen, Michael Wagner and Joachim Tillner are employees of Sanofi-Aventis

The aforementioned second strategy for developing a unimolecular GLP-1R/GcgR dual-agonist, which is the half-life protracted oxyntomodulin-based DualAG, demonstrates superior body weight and food intake reductions to that of a matched GLP-1R mono-agonist control (GLPAG) in WT mice [140]

Sun EW, De Fontgalland D, Rabbitt P, Hollington P, Sposato L, Due SL, et al

In addition to a 2030% reduction in albuminuria compared to placebo, GLP-1 receptor agonists (GLP-1RAs) decelerate the decline of estimated glomerular filtration rate (eGFR) by 12 mL/min/1.73m2 per year relative to usual therapy (Granata et al

Back Kosaka, T, Lim, RSK (June 1930) 'Demonstration of the humoral agent in fat inhibition of gastric secretion', Journal of Experimental Biology and Medicine , 27/9, 890-91